Effect of thymectomy on prognosis in non-thymomatous myasthenia gravis patients with acetylcholine receptor antibody positivity
Öz
Purpose: This study aims to evaluate the one-year clinical follow-up outcomes of Myasthenia Gravis patients who are acetylcholine receptor antibody positive and have undergone thymectomy, and to investigate the effect of thymectomy on prognosis.
Materials and Methods: A total of 94 patients meeting the defined protocol were included in the study. Evaluation continued with 49 patients diagnosed with non-thymomatous myasthenia gravis. Demographic data, medications and dosages used in the pre- and postoperative periods, the need for apheresis and intravenous immunoglobulin before surgery, presence and number of myasthenic crises, postoperative hospital stay, complications (if any), post-discharge treatment plan, current pharmacotherapy and dosages, thymus pathology results, and MGFA (Myasthenia Gravis Foundation of America) stages at preoperative and postoperative 12th month were evaluated comparatively.
Results: The mean age of the included non-thymomatous patients was 42.52 ± 14.89 years. The average postoperative hospital stay was 6.24 ± 2.70 days. It was determined that the dosages of pyridostigmine, steroid and immunosuppressive drugs (azothioprine), decreased in the postoperative period compared to the preoperative period. Positive clinical outcomes (MGFA stage 1 and 2) were observed in 63.3% of the patients and complete clinical remission was achieved in 6.1%.
Conclusion: This study supports the benefit of thymectomy in patients with acetylcholine receptor antibody positive non-thymomatous myasthenia gravis, showing that both severe and mild myastenia gravis patients benefit from thymectomy in the short term and require less medical treatment.
Anahtar Kelimeler
thymectomy, non-thymomatous myastenia gravis, acetylcholine receptor antibody
Destekleyen Kurum
NONE
Etik Beyan
Ethical approval was obtained from the Clinical Research Ethics Committee of Adana City Trai-ning and Researche Hospital by its decision dated 10.07.2025 and numbered 15-604.
Kaynakça
- Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12:259-68.
- Deenen JCW, Horlings CGC, Verschuuren JJGM, Verbeek ALM, van Engelen BGM. The epidemiology of neuromuscular disorders: a comprehensive overview of the Literature. J Neuromuscul Dis. 2015;2:73-85.
- Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia Gravis: Epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10:2235.
- Weiss JM, Cufi P, Le Panse R, Berrih-Aknin S. The thymus in autoimmune myasthenia gravis: paradigm for a tertiary lymphoid organ. Rev Neurol (Paris). 2013;169:640-9.
- Cabrera-Maqueda JM, Alba-Isasi MT, Hernández R, Arroyo-Tristán A, Morales-Ortiz A. [Thymectomy in thymomatous and non-thymomatous myasthenia gravis: analysis of a cohort of 46 patients]. Rev Neurol. 2020;70:213-9.
- Kattach H, Anastasiadis K, Cleuziou J, Buckley C, Shine B, Pillai R et al. Transsternal thymectomy for myasthenia gravis: surgical outcome. Ann Thorac Surg. 2006;81:305-8.
- Yu S, Li F, Chen B, Lin J, Yang M, Fu X et al. Eight-year follow-up of patients with myasthenia gravis after thymectomy. Acta Neurol Scand. 2015;131:94-101.
- Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A et al. MGTX study group. Randomized trial of tymectomy in myasthenia gravis. N Engl J Med. 2016;375:511-22.
- Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A et al. MGTX study group. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol. 2019;18:259-68.
- Cataneo AJM, Felisberto G, Cataneo DC. Thymectomy in nonthymomatous myasthenia gravis - systematic review and meta-analysis. Orphanet J Rare Dis. 2018;13:99.
